[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523807-31-00

Enrollment

Registered

2026-08-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Brief summary

Participants with conversion from atrial fibrillation (AF) to sinus rhythm (SR), sustained for ≥1 minute, within 3 hours after start of study intervention administration, and prior to use of rescue therapy or other SoC for cardioversion

Detailed description

Participants who experienced Treatment Emergent Adverse Events (TEAE)s, Time to conversion from AF to SR as defined in the primary endpoint, Participants in SR, at 3 hours after start of study intervention administration without prior use of rescue therapy or other SoC for cardioversion, Plasma concentration of BAY 3670549 at the end of the infusion

Interventions

DRUGPlacebo to BAY 3670549

DRUGBAY 3670549 Bayer

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Participants with conversion from atrial fibrillation (AF) to sinus rhythm (SR), sustained for ≥1 minute, within 3 hours after start of study intervention administration, and prior to use of rescue therapy or other SoC for cardioversion	—

Secondary

Measure	Time frame
Participants who experienced Treatment Emergent Adverse Events (TEAE)s, Time to conversion from AF to SR as defined in the primary endpoint, Participants in SR, at 3 hours after start of study intervention administration without prior use of rescue therapy or other SoC for cardioversion, Plasma concentration of BAY 3670549 at the end of the infusion	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 8, 2026